Results 231 to 240 of about 12,288 (265)

Association Between COVID-19 Vaccination, Obesity, and Symptom Burden in a Mexican Population: A Retrospective Cross-Sectional Study. [PDF]

Cureus
Bravo-Benítez JM, Bohórquez VC, González-Albarrán D, Rivera-Castro ME, Álvarez-Cortes EP, Pastelin CF, Morán C.   +6 more
europepmc   +1 more source

Immune memory reactivation and T cell dynamics following 12-month homologous CoronaVac booster: a longitudinal cohort study. [PDF]

Front Immunol
Song X, Chen W, Bai S, Lv M, Wang J, Zhang A, Wu J, Zhao W.   +7 more
europepmc   +1 more source

Polymorphism in IFNλ Can Impact the Immune/Inflammatory Response to COVID-19 Vaccination in Older CMV-Seropositive Adults. [PDF]

Vaccines (Basel)
Nardy A, Monteiro FR, Silva BR, do Amaral JB, Leal Oliveira DB, Cândido ÉDO, Luiz Durigon E, Aguiar AS, Scagion GP, Chalup VN, Furtado GE, Shio MT, França CN, Nali LHDS, Bachi ALL.   +14 more
europepmc   +1 more source

Clinical, epidemiological, and laboratory analysis of hospitalized and fatal COVID-19 cases in the first fully vaccinated municipality in Northeast Brazil. [PDF]

Rev Inst Med Trop Sao Paulo
Costa LB, Nobre AP, Santos MESD, Farias LABG, Almeida MM, Bekman ALS, Souza SS, Barreto FKA, Máximo ACBM, Silva DB, Freire de Freitas RWJ, Cavalcanti LPG.   +11 more
europepmc   +1 more source

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial [PDF]

Nature Medicine, 2022
AbstractThe emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and the waning of vaccine-elicited neutralizing antibodies suggests that additional coronavirus disease 2019 (COVID-19) vaccine doses may be needed for individuals who initially received CoronaVac. We evaluated the safety and immunogenicity of the recombinant
Jingxin Li, Lihua Hou, Pengfei Jin
exaly   +6 more sources

CoronaVac efficacy data from Turkey [PDF]

Lancet, The, 2021
Ben Cowling
exaly   +3 more sources

Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil [PDF]

Nature Medicine, 2022
AbstractThere is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of
Thiago Cerqueira-Silva, Srinivasa Katikireddi, Vinícius de Araújo Oliveira   +2 more
exaly   +8 more sources

CoronaVac: more data for regulators and policy makers [PDF]

Lancet, The, 2021
Maheshi N Ramasamy
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Dynamics of antibody response to CoronaVac vaccine

Journal of Medical Virology, 2022
AbstractCoronaVac was the first vaccine approved in Brazil for use in healthcare workers (HCWs). However, there is limited information about it, with little long‐term evidence on post‐vaccination antibody persistence. This study evaluated the antibody response to SARS‐CoV‐2 in 1237 HCWs after the first (1D), second dose (2D), and 6 months ...
Marcela Helena Gambim Fonseca, Tamiris de Fátima Goebel de Souza, Fernanda Montenegro de Carvalho Araújo, Luiz Odorico Monteiro de Andrade   +3 more
openaire   +2 more sources